Status:
COMPLETED
Best Therapy for Patients With Neuroendocrine Tumors
Lead Sponsor:
Zentralklinik Bad Berka
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18-90 years
Brief Summary
A prospective observational study containing three arms comprising different therapeutic measures to treat patients with neuroendocrine tumors in advanced stages. The therapy arms include local ablati...
Detailed Description
Study design: Prospective observational study comparing ablative measures as TACE or SIRT with surgery/RFA and with peptide receptor radio-therapy in patients with advanced well-differentiated neuroe...
Eligibility Criteria
Inclusion
- Biopsy-proven neuroendocrine tumor (WHO class I-II, TNM grading 1-2)
- Advanced disease with lymph node or distant metastases (N1, M1) undergoing cytoreduction by surgery/local ablative therapy or peptide receptor radiotherapy
- curative intent of all therapies possible
Exclusion
- Undifferentiated neuroendocrine carcinoma (WHO class III, TNM grading 3)
- secondary tumor
- advanced carcinoid heart disease requiring surgery
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00815620
Start Date
November 1 2008
End Date
March 1 2017
Last Update
March 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zentralklinik Bad Berka
Bad Berka, Germany, 99437